AU7638091A - Muteins of the granulocyte colony stimulating factor (g-csf) - Google Patents

Muteins of the granulocyte colony stimulating factor (g-csf)

Info

Publication number
AU7638091A
AU7638091A AU76380/91A AU7638091A AU7638091A AU 7638091 A AU7638091 A AU 7638091A AU 76380/91 A AU76380/91 A AU 76380/91A AU 7638091 A AU7638091 A AU 7638091A AU 7638091 A AU7638091 A AU 7638091A
Authority
AU
Australia
Prior art keywords
muteins
csf
stimulating factor
colony stimulating
granulocyte colony
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU76380/91A
Other versions
AU631312B2 (en
Inventor
Carola Dony
Gunther Schumacher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Boehringer Mannheim GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim GmbH filed Critical Boehringer Mannheim GmbH
Publication of AU7638091A publication Critical patent/AU7638091A/en
Application granted granted Critical
Publication of AU631312B2 publication Critical patent/AU631312B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B23—MACHINE TOOLS; METAL-WORKING NOT OTHERWISE PROVIDED FOR
    • B23K—SOLDERING OR UNSOLDERING; WELDING; CLADDING OR PLATING BY SOLDERING OR WELDING; CUTTING BY APPLYING HEAT LOCALLY, e.g. FLAME CUTTING; WORKING BY LASER BEAM
    • B23K26/00—Working by laser beam, e.g. welding, cutting or boring
    • B23K26/351—Working by laser beam, e.g. welding, cutting or boring for trimming or tuning of electrical components
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Mechanical Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plasma & Fusion (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU76380/91A 1990-05-08 1991-05-06 Muteins of the granulocyte colony stimulating factor (g-csf) Ceased AU631312B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4014750A DE4014750A1 (en) 1990-05-08 1990-05-08 MUTEINE OF THE GRANULOCYTE-STIMULATING FACTOR (G-CSF)
DE4014750 1990-05-08

Publications (2)

Publication Number Publication Date
AU7638091A true AU7638091A (en) 1991-11-14
AU631312B2 AU631312B2 (en) 1992-11-19

Family

ID=6405959

Family Applications (1)

Application Number Title Priority Date Filing Date
AU76380/91A Ceased AU631312B2 (en) 1990-05-08 1991-05-06 Muteins of the granulocyte colony stimulating factor (g-csf)

Country Status (17)

Country Link
EP (1) EP0456200A1 (en)
JP (1) JPH04225998A (en)
KR (1) KR940000757B1 (en)
CN (1) CN1057862A (en)
AU (1) AU631312B2 (en)
CA (1) CA2041439A1 (en)
CS (1) CS133391A3 (en)
DE (1) DE4014750A1 (en)
FI (1) FI912203A (en)
HU (1) HUT58801A (en)
IE (1) IE911359A1 (en)
IL (1) IL98070A0 (en)
NO (1) NO911786L (en)
NZ (1) NZ237975A (en)
PL (1) PL290166A1 (en)
PT (1) PT97611A (en)
ZA (1) ZA913430B (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5536495A (en) * 1994-04-15 1996-07-16 Foster; Preston F. Use of G-CSF to reduce acute rejection
US5718893A (en) * 1984-04-15 1998-02-17 Foster; Preston F. Use of G-CSF to reduce acute rejection
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US6790628B2 (en) 2000-09-08 2004-09-14 Massachusetts Institute Of Technology Method for screening analogs of G-CSF
US6956027B2 (en) 1994-10-12 2005-10-18 Amgen Inc. N-terminally chemically modified protein compositions and methods
US7220407B2 (en) 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
EP1998266A2 (en) 2001-02-19 2008-12-03 Merck Patent GmbH Method for identification of T-cell epitopes and use for preparing molecules with reduced immunogenicity
US7662933B2 (en) 1994-10-12 2010-02-16 Amgen Inc. N-terminally chemically modified protein compositions and methods
EP2186525A2 (en) 2002-12-31 2010-05-19 SYGNIS Bioscience GmbH & Co KG G-CSF for use in the treatment of Parkinson's disease
EP2295069A1 (en) 2004-06-30 2011-03-16 Sygnis Bioscience GmbH & Co. KG Treatment of neurological disorders with haematopoietic growth factors
EP2345724A1 (en) 1993-01-28 2011-07-20 Amgen Inc. G-CSF analog compositions and methods
US8455218B2 (en) 2010-04-01 2013-06-04 Pfenex, Inc. Methods for G-CSF production in a Pseudomonas host cell
US8481022B2 (en) 2007-08-09 2013-07-09 Genzyme Corporation Method of treating autoimmune disease with mesenchymal stem cells
US8524655B2 (en) 2004-11-05 2013-09-03 Northwestern University Use of SCF and G-CSF in the treatment of cerebral ischemia and neurological disorders
US8758761B2 (en) 2007-09-30 2014-06-24 University Of Florida Research Foundation, Inc. Combination therapies for treating type 1 diabetes
US9187543B2 (en) 2010-03-04 2015-11-17 Pfenex Inc. Method for producing soluble recombinant interferon protein without denaturing

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9107846D0 (en) * 1990-04-30 1991-05-29 Ici Plc Polypeptides
KR100440460B1 (en) * 1998-07-08 2004-10-08 주식회사유한양행 Gene, recombinant vector and transformant of hG-CSF and method of producing hG-CSF using the same
DE19860801A1 (en) * 1998-12-30 2000-07-06 Rhein Biotech Proz & Prod Gmbh Recombinant growth factor with the biological activity of a G-CSF (Granulocyte Colony Stimulating Factor)
EP1425304B9 (en) 2001-07-11 2010-09-08 Maxygen, Inc. G-csf conjugates
DE102004041639A1 (en) 2004-08-27 2006-03-02 Bioceuticals Arzneimittel Ag Method for obtaining biologically active human G-CSF from inclusion bodies
CN101193658B (en) 2005-06-01 2011-08-31 马克西根控股公司 Pegylated G-CSF polypeptides and methods of producing same
DE102005033250A1 (en) 2005-07-15 2007-01-18 Bioceuticals Arzneimittel Ag Process for purifying G-CSF
DE102006009437A1 (en) 2006-03-01 2007-09-13 Bioceuticals Arzneimittel Ag G-CSF liquid formulation
BRPI0815280A2 (en) 2007-08-27 2018-11-27 Biogenerix Ag medicament comprising an aqueous liquid formulation of g-csf, receptacle for the administration of liquid medicaments, syringe or ampoule, kit for parenteral administration of g-csf
DE102007040932A1 (en) 2007-08-27 2009-03-05 Biogenerix Ag Liquid granulocyte colony-stimulating factor formulation, e.g. for treating cancer, neutropenia, HIV infections or neurological disorders, comprises a sugar alcohol, surfactant and acetate buffer
JP5570988B2 (en) 2007-08-27 2014-08-13 ラティオファーム ゲーエムベーハー Liquid preparation of G-CSF conjugate
EP2399572A1 (en) 2010-06-22 2011-12-28 Sandoz AG Long-term storage of non-glycosylated recombinant human G-CSF

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06102021B2 (en) * 1985-12-03 1994-12-14 中外製薬株式会社 Novel polypeptide
JPS63500636A (en) * 1985-08-23 1988-03-10 麒麟麦酒株式会社 DNA encoding multipotent granulocyte colony stimulating factor
EP0256843A1 (en) * 1986-08-11 1988-02-24 Cetus Corporation Expression of g-csf and muteins thereof and their use
WO1988003173A2 (en) * 1986-10-24 1988-05-05 Cetus Corporation New forms of colony stimulating factor-1
DK174044B1 (en) * 1986-12-23 2002-05-06 Kyowa Hakko Kogyo Kk Polypeptide derived from human granulocyte colony stimulating factor, and method of preparation thereof, DNA encoding said polypeptide, recombinant plasmid containing said DNA, and microorganisms containing said recombinant plasmid .......

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5718893A (en) * 1984-04-15 1998-02-17 Foster; Preston F. Use of G-CSF to reduce acute rejection
US8058398B2 (en) 1993-01-28 2011-11-15 Amgen Inc. Modified G-CSF polypeptide
EP2345724A1 (en) 1993-01-28 2011-07-20 Amgen Inc. G-CSF analog compositions and methods
US5536495A (en) * 1994-04-15 1996-07-16 Foster; Preston F. Use of G-CSF to reduce acute rejection
US7662933B2 (en) 1994-10-12 2010-02-16 Amgen Inc. N-terminally chemically modified protein compositions and methods
US8258262B2 (en) 1994-10-12 2012-09-04 Amgen Inc. N-terminally chemically modified protein compositions and methods
EP2392594A1 (en) 1994-10-12 2011-12-07 Amgen Inc. N-terminally monopegylated polypeptides and process for their preparation
US6956027B2 (en) 1994-10-12 2005-10-18 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6979674B1 (en) 1998-12-23 2005-12-27 Amgen Inc. Polyol/oil suspensions for the sustained release of proteins
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US7371370B2 (en) 2000-09-08 2008-05-13 Massachusetts Institute Of Technology Methods of using G-CSF analog compositions
US7402304B2 (en) 2000-09-08 2008-07-22 Massachusetts Institute Of Technology Methods of using G-CSF analog compositions
US6946548B2 (en) 2000-09-08 2005-09-20 Massachusetts Institute Of Technology G-CSF analog compositions and methods
US6790628B2 (en) 2000-09-08 2004-09-14 Massachusetts Institute Of Technology Method for screening analogs of G-CSF
EP1998266A2 (en) 2001-02-19 2008-12-03 Merck Patent GmbH Method for identification of T-cell epitopes and use for preparing molecules with reduced immunogenicity
EP2186525A2 (en) 2002-12-31 2010-05-19 SYGNIS Bioscience GmbH & Co KG G-CSF for use in the treatment of Parkinson's disease
EP2311483A1 (en) 2002-12-31 2011-04-20 SYGNIS Bioscience GmbH & Co KG GCSF for use in treating a neurological disease with pathophysiological mechanisms involving ischemia or hypoxia
US7220407B2 (en) 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
EP2295069A1 (en) 2004-06-30 2011-03-16 Sygnis Bioscience GmbH & Co. KG Treatment of neurological disorders with haematopoietic growth factors
US8524655B2 (en) 2004-11-05 2013-09-03 Northwestern University Use of SCF and G-CSF in the treatment of cerebral ischemia and neurological disorders
US8481022B2 (en) 2007-08-09 2013-07-09 Genzyme Corporation Method of treating autoimmune disease with mesenchymal stem cells
US8758761B2 (en) 2007-09-30 2014-06-24 University Of Florida Research Foundation, Inc. Combination therapies for treating type 1 diabetes
US9187543B2 (en) 2010-03-04 2015-11-17 Pfenex Inc. Method for producing soluble recombinant interferon protein without denaturing
US9611499B2 (en) 2010-03-04 2017-04-04 Pfenex Inc. Method for producing soluble recombinant interferon protein without denaturing
US8455218B2 (en) 2010-04-01 2013-06-04 Pfenex, Inc. Methods for G-CSF production in a Pseudomonas host cell

Also Published As

Publication number Publication date
KR940000757B1 (en) 1994-01-29
NO911786D0 (en) 1991-05-07
ZA913430B (en) 1992-02-26
CA2041439A1 (en) 1991-11-09
HU911529D0 (en) 1991-11-28
HUT58801A (en) 1992-03-30
EP0456200A1 (en) 1991-11-13
CN1057862A (en) 1992-01-15
AU631312B2 (en) 1992-11-19
FI912203A0 (en) 1991-05-07
DE4014750A1 (en) 1991-11-14
PT97611A (en) 1992-03-31
PL290166A1 (en) 1992-01-13
NO911786L (en) 1991-11-11
KR910020033A (en) 1991-12-19
FI912203A (en) 1991-11-09
IE911359A1 (en) 1991-11-20
JPH04225998A (en) 1992-08-14
CS133391A3 (en) 1992-01-15
IL98070A0 (en) 1992-06-21
NZ237975A (en) 1992-09-25

Similar Documents

Publication Publication Date Title
AU631312B2 (en) Muteins of the granulocyte colony stimulating factor (g-csf)
AU6351194A (en) Pulmonary administration of granulocyte colony stimulating factor
AU7675487A (en) Expression of granulocyte colony-stimulating factor
AU7566587A (en) Stable pharmacuetical preparation containing granulocyte colony stimulating factor and process for producing the same
AU626639B2 (en) Recombinant colony stimulating factor-1
AU2377592A (en) Biomedical electrode
AU7184487A (en) Human g-csf protein expression
AU3196195A (en) Muteins of mammalian cytokines
AU9089591A (en) Inhaler
AU8751391A (en) Inhaler
AU1441792A (en) Megakaryocyte stimulating factors
AU5541786A (en) Games tables
AU6482898A (en) Leukocyte-derived growth factor
AU1152783A (en) Interferon alpha 76
AU586540B2 (en) Powder booth
AU1181283A (en) Homogenous human immune interferon
AU4193685A (en) Human interferon epsilon
AU2716288A (en) Neutrophil-activating factor
AU1152983A (en) Interferon alpha 74
AU8313187A (en) Pharmaceutical composition of colony stimulating factor-i and granulocyte colony stimulating factor
AU3149684A (en) Therapeutic table
AU7972991A (en) Novel megakaryocyte colony stimulating factor and production thereof
AU3532289A (en) Novel bovine granulocyte-macrophage colony stimulating factor variant
AU2266983A (en) Dental fume cupboard
AU7578091A (en) Treatment of cachexia with interleukin 2